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and Clayton Trimmer, DO,d Dallas, Tex
Background: The purpose of the current study was to identify clinical and kidney morphologic features that predict a
favorable blood pressure (BP) response to renal artery stenting (RAS).
Methods: The study cohort consisted of 149 patients who underwent primary RAS over 9 years. Patients were categorized
as “responders” based on modified American Heart Association guidelines: BP <160/90 mm Hg on fewer antihyper-
tensive medications or diastolic BP <90 mm Hg on the same medications. All other patients were deemed “nonre-
sponders.” Renal volume was estimated as kidney length  width  depth/2 based on preoperative computed
tomography or magnetic resonance scans. Median follow-up was 19 months (interquartile range [IQR] 10.0-29.5
months).
Results: The median age of the cohort was 68 years (IQR, 60-74 years). A favorable BP response was observed in 50 of
149 patients (34%). Multivariate analysis identified three independent predictors of a positive BP response: (1)
requirement for four or more medications (odds ratio, 29.9; P .0001), (2) preoperative diastolic BP>90 mm Hg (OR,
31.4; P .0011), and (3) preoperative clonidine use (OR, 7.3; P .029). The BP response rate varied significantly based
on the number of predictors present per patient (P < .0001). Among patients with three-drug hypertension, a larger
ipsilateral kidney (volume >150 cm3) increased the BP response rate more than threefold compared with patients with
smaller kidneys (63% vs 18% BP response rate; P  .018).
Conclusions:The current study demonstrated that three clinical predictors (>4 antihypertensive medications, diastolic BP
>90 mm Hg, and clonidine use) are preoperative predictors of BP response to RAS. Kidney volume may help in
discriminating responders from nonresponders among those patients with three-drug hypertension. These parameters
may assist clinicians in patient selection and provide more concrete data with which to counsel patients on the likely
outcomes for RAS. (J Vasc Surg 2011;53:1282-90.)
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pIn most centers, renal artery stenting (RAS) has be-
come first-line therapy for the treatment of renovascular
hypertension and ischemic nephropathy. In recent years,
however, RAS has been the subject of considerable scrutiny
by governmental agencies that have openly expressed skep-
ticism regarding the role of RAS in the treatment of renal
artery occlusive disease. In 2006 the Agency for Healthcare
Research andQuality (AHRQ) stated, “there has been little
high-quality evidence . . . to support the relative benefit of
angioplasty, with or without stents, compared to aggressive
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1282edical treatment.”1 In 2007, the Center forMedicare and
edicaid Services (CMS) questioned whether reimburse-
ent for RAS should be continued.2 Although the pro-
osal to terminate reimbursement for RAS was rescinded
y CMS in 2008, the questions raised by AHRQ and CMS
re a clear mandate for additional data on the indications,
enefits, and outcomes for RAS.
Unfortunately, the results of a recent randomized clin-
cal trial, the Angioplasty and Stenting for Renal Artery
esions (ASTRAL) trial, did nothing to mitigate concerns
bout RAS. The ASTRAL trial reported no difference in
ystolic blood pressure (BP), diastolic BP, or rate of pro-
ression of renal impairment betweenmedically treated and
AS cohorts.3 Some authors have openly dismissed the
esults of the ASTRAL trial based on contentions that the
rial’s inclusion criteria were overly liberal.4 Nonetheless,
he ASTRAL trial inadvertently raised an important ques-
ion that undoubtedly affects the outcomes for RAS:Which
atients are most likely to benefit from RAS and who
hould not undergo RAS? Currently, there are few data to
nform decisions regarding patient selection for RAS.
Contrary to the ASTRAL trial, data from multiple
ingle-center studies have demonstrated improved BP or
enal function in a significant proportion (42% to 80%) of
atients after RAS.5-8 A thread common to each of these
tudies, however, was the observation that a substantial
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Volume 53, Number 5 Modrall et al 1283subset of patients (20% to 58%) failed to show any improve-
ment in BP or renal function after RAS.5,7,8 It is perhaps
not surprising that the results for RAS are relatively unpre-
dictable in view of the relative lack of evidence-based guide-
lines to direct patient selection. To address this knowledge
gap, the current study was aimed at characterizing the
“phenotype” of patients who had a favorable BP response
to RAS (responders) compared with patients who derived
no benefit (nonresponders). We hypothesize that there are
clinical, morphologic, and biochemical markers that can
distinguish responders from nonresponders. In the current
study, the specific goal was to identify clinical and kidney
morphologic features that predict a favorable BP response
to RAS.
METHODS
Study population and clinical data collection. The
study cohort consisted of 149 patients who underwent
primary RAS by clinicians in the Departments of Surgery
and Radiology at the University of Texas Southwestern
Medical Center and its affiliated hospitals between January
1, 2000, and July 1, 2008. A retrospective review of these
patients is reported. The study was approved by the Insti-
tutional Review Boards of the participating institutions.
Patients who underwent RAS by cardiologists were not
included in the study cohort. Exclusion criteria included
nonatherosclerotic lesions and treatment of secondary le-
sions after prior angioplasty or stenting.
Standard demographic, clinical, and anatomic data rel-
evant to RAS were collected. The average preoperative BP
was calculated from two to three preoperative clinic visits
per patient. BP readings obtained on the day of the stenting
procedure were excluded from this analysis. When BP was
measured in both arms, the one with the higher BP was
used. If multiple measurements were performed in a single
arm, the average BP for that encounter was calculated. The
number of antihypertensive medications was noted for each
patient, including all medications that have known effects
on BP regardless of the indication for use. As such, diuretics
and nitrates used daily for control of cardiac symptoms were
included in the tally of medications. Preoperative estimated
glomerular filtration rate (eGFR) was recorded; patients on
dialysis were represented with an eGFR of 10 mL/min/
1.73 m2.
At stenting, the number of renal arteries treated (uni-
lateral vs bilateral RAS) and the status of the contralateral
kidney were noted. Because identifying preoperative clini-
cal and kidney morphologic predictors of BP response was
the primary goal of the study, only minimal procedural
details are reported. After the procedure, the same indexes
of BP control and renal function were collected from the
last follow-up visit. Records were scrutinized for evidence
of in-stent restenosis during follow-up.
Definition of blood pressure response. The primary
end point of the study was BP response to RAS. For the
purpose of analyzing patient-specific responses to RAS, a
modification of American Heart Association guidelines9was used to categorize patients as responders or nonre- mponders based on a comparison of pretreatment and post-
reatment BP and medications. Based on data from the last
ollow-up, BP responders were defined by an average post-
perative BP 160/90 mm Hg on a reduced number of
ntihypertensive medications or a reduction in average
iastolic BP to90 mmHg on the same medications after
AS. All other patients were deemed nonresponders. Pa-
ients were categorized as responders or nonresponders
ased on data from the most recent follow-up visits. No
atients were included with 1 month of follow-up.
Kidney morphometrics. In 86 of 149 patients
57.7%), preoperative contrast-enhanced computed to-
ography (CT) or magnetic resonance (MR) scans were
dequate to measure parameters of kidney morphology.
easurements included kidney pole-to-pole length, medi-
l-to-lateral kidney width, and anterior-to-posterior kidney
epth. The estimated renal volume was calculated from
hese measurements: kidney length  width  (depth/
).10,11 All measurements were performed in duplicate and
veraged for each stented kidney.
Statistical analysis. The primary end point of the
tudy was BP response. Continuous data were reported as
edians with interquartile ranges (IQR) and compared
etween responders and nonresponders using Wilcoxon
atched pairs tests andMann-WhitneyU tests as appropri-
te. Categorical data were analyzed using 2 square, Fisher
xact, or Cochran-Armitage trend tests as indicated.
We used multiple logistic regression models to identify
redictors of BP response. We first used a traditional logis-
ic regression model to identify patient-level predictors of
P response in the entire cohort of 149 patients. We chose
redictors that were significant on univariate analysis (P 
05) in the model and entered them as clinically relevant
hresholds. This model included no data specific to a par-
icular kidney within an individual. We then used a mixed
ultiple regression (SAS GLIMMIX PROC) to identify
atient-level and kidney-level predictors of BP response in
he cohort with complete imaging data (86 patients with
10 stented kidneys). In addition to the fixed effects, the
able I. Cohort demographics (n  149)
Risk factor
Median (IQR) or
No. (%)
Age, years 68 (60-74)
Female gender 77 (51.7)
Race
White 96 (64.4)
African-American 33 (22.1)
Hispanic/Other 20 (13.4)
Hypertension 149 (100)
Chronic renal insufficiency 74 (49.7)
Diabetes 54 (36.2)
Coronary artery disease 85 (57.0)
Hyperlipidemia 61 (40.1)
Tobacco history 132 (88.6)
COPD 34 (22.8)
OPD, Chronic obstructive pulmonary disease; IQR, interquartile range.ixed regression model included random patient effects to
d
m
m

m
c
s
(
m
r
i
m
w
t
a
p
a
p
w
n
r
a
p
h
r
t
w
r
a
f
t
r
f
b
m
e
T
(
P
B
A
S
e
e
a
b
JOURNAL OF VASCULAR SURGERY
May 20111284 Modrall et alaccommodate the two-level, hierarchical structure of the
data in which kidneys are nested within patients. Of note,
the cohort with imaging data was not significantly different
from the cohort without imaging data in age, baseline
systolic and diastolic BP, number of medications, and renal
function (data not shown). For all statistical analyses, the
threshold for significance was .05. Statistical analysis was
performed using SAS 9.13 software (SAS Institute, Inc,
Cary, NC).
RESULTS
Baseline cohort characteristics. Cohort demograph-
ics are summarized in Table I. The median age of the RAS
cohort was 68 years (IQR, 60-74 years) with nearly equal
proportions of males and females. Hypertension was pres-
ent in all patients, while renal insufficiency (serum creati-
nine 1.5 mg/dL) was present in half of patients. The
cohort had the typical comorbidities that characterize this
atherosclerotic patient population (Table I).
At baseline, the median preoperative systolic BP was
151 mm Hg (IQR, 140-175 mm Hg), and the median
preoperative diastolic BP was 79 mm Hg (IQR, 69-88
mm Hg). Patients were taking a median of three (IQR,
2-4) antihypertensive medications. Eight patients re-
quired hemodialysis preoperatively. Among patients who
did not require renal replacement therapy, the median
preoperative serum creatinine was 1.4 mg/dL (IQR,
1.0-1.8 mg/dL).
Cohort outcomes. RAS was performed in 149 pa-
tients (185 arteries). Two immediate major complications
occurred. A branch renal artery perforation by a guidewire
occurred in one patient that was managed nonoperatively.
Another patient had atheroembolization to the lower ex-
tremity that required endovascular salvage in the early
postoperative period. Bilateral stenting was performed in
36 of 149 patients (24%). Ten solitary kidneys were treated
with RAS.
Median follow-up was 19.0 months (IQR, 10.0-29.5
months). The outcomes after RAS for the entire cohort,
analyzed in aggregate, are outlined in Table II. At last
follow-up, the median postoperative systolic BP, 137
mm Hg (IQR, 124-151 mm Hg), was significantly de-
creased by RAS compared with prestenting systolic pres-
sures (P  .0001). Similarly, median postoperative dia-
stolic BP, 70 mm Hg (IQR, 64-79 mm Hg), was
significantly lower after RAS (P  .0001). Patients re-
quired a median of three postoperative medications
(IQR 2.5-4), which was unchanged by RAS (P  .99).
The median serum creatinine (1.3 [IQR, 1.0-1.8 mg/
dL]) and eGFR (49 [IQR, 33-60 mL/min/1.73 m2])
were also unchanged by stenting compared with baseline
(P  .40 and P  .85, respectively).
Patient-specific outcomes. Using a standardized
definition to categorize patients as responders or nonre-
sponders, a much different picture of RAS emerged.
Only 50 of 149 patients (34%) were BP responders.
Responders had a median decrease in systolic BP of 33
mm Hg (IQR, 15 to 47 mm Hg) and a median kecrease in diastolic BP of 15 mm Hg (IQR, 7 to 25
mHg) after RAS. By comparison, nonresponders had a
edian decrease in systolic BP of 8 mm Hg (IQR, 5 to
24 mm Hg) and a median decrease in diastolic BP of 2
m Hg (IQR, 3 to 12 mm Hg) with stenting. The
hanges in systolic and diastolic BP due to stenting were
ignificantly greater for responders than nonresponders
P  .0001). The median change in the number of BP
edications after stenting was one less medication for
esponders (IQR, 1 to 2 less medications) and no change
n medications for nonresponders (IQR, zero to one
edication), which was significant (P  .0001).
Responders and nonresponders were then compared
ith univariate analyses to identify preoperative parameters
hat may be associated with a higher likelihood of a favor-
ble response to RAS (Table III). Patients with an im-
roved BP after RAS were significantly more likely to have
higher systolic BP, a higher diastolic BP, and require more
reoperative antihypertensive medications. Responders
ere more likely to be treated with clonidine as a compo-
ent of their antihypertensive regimen. Age, gender, and
ace were not significantly different between responders
nd nonresponders. The median eGFR and proportion of
atients requiring dialysis, undergoing bilateral RAS, or
aving a solitary kidney did not differ significantly between
esponders and nonresponders. Multiple renal arteries on
he side of intervention were uncommon (n 4), and those
ere equally distributed between responders and non-
esponders.
The relationship between the number of preoperative
ntihypertensive medications and BP response to RAS is
urther defined in Fig 1. A dramatic difference was noted in
he BP response rate based on the number of medications
equired for BP control. Most patients requiring three or
ewer medications at baseline failed to derive any significant
enefit in BP control from RAS. Only when four drugs or
ore were required did the proportion of BP responders
xceed 50%.
Kidney morphology. The status of the end organ, the
able II. Cohort outcomes after renal artery stenting
n  149)a
arameter
Preoperative Postoperative
Pbmedian (IQR) median (IQR)
lood pressure,
mm Hg
Systolic 151 (140-175) 137 (124-151) .0001
Diastolic 79 (69-88) 70 (64-79) .0001
ntihypertensive
drugs 3 (2.0-4.0) 3 (2.5-4.0) .99
erum creatinine,
mg/dL 1.4 (1.0-1.8) 1.3 (1.0-1.8) .40
GFR, mL/min/
1.73 m2 48 (33-60) 49 (33-60) .85
GFR, Estimated glomerular filtration rate; IQR, interquartile range.
Cohort data are analyzed in aggregate.
P values by Wilcoxon matched pairs test.idney, is another variable that may affect outcomes for
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enhanced CT or MR scans to permit measurements of
kidney morphology on 110 kidneys. Kidney length, width,
and depth were not significantly different between re-
sponders and nonresponders (Table IV). Interestingly, the
calculated kidney volume of the ipsilateral kidney was sig-
nificantly greater among responders than nonresponders
(Table IV). To further define the relationship between
kidney volume and BP response to RAS, the response rate
for RAS was plotted for various intervals of kidney volume
(Fig 2). From this graph, it is apparent that there was a
direct relationship between kidney volume and the BP
Fig 1. Number of antihypertensivemedications (MEDS
responders (with error bars showing 95% confidence
medications required. P  .0001 (2 for trend).
Table III. Comparison of preoperative clinical parameters
Preoperative variable
Res
(n
Age, years 69 (6
Gender (% females) 5
Race, %
White 6
African-American 2
Hispanic/other 1
Blood pressure, mean (IQR) mm Hg
Systolic 170 (1
Diastolic 90 (7
Diastolic blood pressure 90 mm Hg, % 5
Medications, median No. (IQR) 4.0 (3
Clonidine use, % 3
eGFR, mean mL/min/1.73 m2 (IQR) 41 (3
Hemodialysis, %
Bilateral stenting, % 3
Solitary kidney, %
eGFR, Estimated glomerular filtration rate; IQR, interquartile range.
Categorical were compared with 2 or Fisher exact test as appropriate. Conresponse to RAS (P  .007, 2 for trend). tMultivariate analysis. Multivariate analysis was per-
ormed to identify preoperative parameters that may be
ndependent predictors of BP response to stenting. Mixed
ultiple regression identified three variables that were sig-
ificant: (1) requirement for four or more antihypertensive
edications, (2) preoperative diastolic BP 90 mm Hg,
nd (3) preoperative clonidine use (Table V). A traditional
tepwise forward logistic regression analysis on the entire
ohort of 149 patients confirmed that the three parameters
ere also significant predictors within the parent study
opulation after excluding kidney-specific data. The C sta-
istic for the model was .90, indicating an excellent ability
blood pressure (BP) response rate. The proportion of BP
vals) varies according to the number of preoperative
onders vs nonresponders
rs Nonresponders
P) (n  99)
) 68 (60-74) .27
53.5 .53
.61
66.3
19.8
13.9
8) 146 (134-162) .0001
) 76 (66-83) .0001
8.1 .0001
5.0) 3.0 (2.0-3.0) .0001
13.9 .0004
52 (35-60) .20
7.1 .27
19.2 .07
9.1 .34
s data were compared with Mann-Whitney U test.) and
inter, resp
ponde
 50
1-75
7.9
0.4
7.1
2.5
43-18
2-100
2
.5 to
9.6
2-60)
2.0
4.0
4.0o discriminate BP responders from nonresponders. The
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respectively. The positive predictive value was 0.64,
whereas the negative predictive value was 0.94. The R2 for
the model was 0.43, indicating that less than half of the
variance in outcomes could be explained by the three
predictors from the model.
The three clinical predictors we identified often oc-
curred in combination within patients, which we believe
may have utility in predicting the clinical response to RAS.
The cumulative effect of multiple predictors on the proba-
bility of a BP response to RAS is apparent from Fig 3. The
absence of any of the three clinical predictors of response
that we identified was associated with nearly universal fail-
ure to respond to stenting with an improvement in BP. The
BP response rate vastly improved with each additional
predictor.
Kidney volume was not a significant predictor of BP
response on multivariate analysis using the mixed regres-
sion model. However, we believe that kidney volume re-
mains a useful parameter to discriminate potential respond-
ers from nonresponders among patient subsets who are
marginal candidates for stenting, such as those with three-
drug hypertension. For example, patients with three-drug
hypertension and ipsilateral kidney volume 150 cm3 had
an 18% BP response rate to stenting, whereas the BP
response rate increased 63% if greater kidney mass (volume
150 cm3) was present (P  .018).
The utility of kidney volume in predicting outcomes is
further illustrated for the subset of patients with a serum
creatinine1.5mg/dL. In the current study, imaging tests
for the calculation of kidney volume were available for 50 of
the 74 patients with a serum creatinine 1.5 mg/dL.
Within this subset of 50 patients, 19 (38%) were BP re-
sponders. A comparison of renal volume among patients
with a serum creatinine 1.5 mg/dL revealed a kidney
volume of 137.0 cm3 (IQR, 115.5-183.0 cm3) for re-
sponders, which was significantly higher than the 117.3
cm3 (IQR, 98.4-154.1 cm3; P  .025) for nonresponders
with similar kidney function.
DISCUSSION
The 2006 American Heart Association Practice Guide-
Table IV. Kidney morphometrics
Variable
Responders Nonresponders
Pa
(n  33) (n  53)
Median (IQR) Median (IQR)
Ipsilateral
kidney
Length, cm 10.1 (9.6-10.5) 9.6 (8.9-10.6) .07
Width, cm 5.7 (4.0-6.2) 5.5 (4.9-6.1) .14
Depth, cm 5.1 (4.9-5.7) 5.1 (4.5-5.6) .41
Volume,
cm3 151.6 (128.3-189.5) 136.1 (105/1-155.9) .01
IQR, Interquartile range.
aCalculated by Mann-Whitney U test.lines stated that RAS is “reasonable” in patients with “ac- kelerated hypertension, resistant hypertension, malignant
ypertension, hypertension with an unexplained unilateral
mall kidney, and hypertension with intolerance to medica-
ion.”12 In practice, such guidelines are vague and nonspe-
ific, leaving the clinician with little solid data on which to
ase patient selection. Moreover, it is difficult to offer
atients an estimate on the probability of BP response to
AS. The clinical consequence has been unpredictable
esults for RAS, with as many as 20% to 58% of patients
eriving no improvement in BP or renal function from the
rocedure.5,7,8 The goal of the current study was to address
his knowledge gap by identifying clinical and morphologic
redictors of a favorable BP response to RAS. By compar-
ng responders to nonresponders, we identified three clin-
cally relevant predictors of BP response: (1) requirement
or 4 antihypertensive medications; (2) preoperative dia-
tolic BP90 mmHg; and (3) preoperative clonidine use.
lthough not significant in the study population at large,
ur data also suggest that kidney volume 150 cm3 may
lso have utility in distinguishing responders from nonre-
ponders among patients with three-drug hypertension.
It is perhaps not surprising that the severity of hyper-
ension, as indicated by the number of medications, pres-
nce of diastolic hypertension, and use of clonidine, corre-
ates with a higher probability of response to RAS. Since the
arliest days of renal artery bypass surgery, it was known the
everity of hypertension is a marker for improved BP re-
ponse to surgery.13 To assist clinicians with patient selec-
ion, we constructed a “dose-response” graph (Fig 1) to
emonstrate how the BP response rate varies with increas-
ng numbers of medications.
It is apparent that a minority of patients with one-,
wo-, or three-drug hypertension will see a significant im-
rovement in BP. For instance, using three-drug hyperten-
ion as the threshold for stenting, as proposed in the
merican Heart Association (2006) Practice Guidelines,12
ur data indicate that there is a 19% probability of a BP
esponse to RAS (Fig 1). The addition of either diastolic
ypertension or clonidine use increases the probability of a
P response. The likely relevance of clonidine to this algo-
ithm is that it is another means of identifying patients with
ypertension that is “difficult to control.” Most hyperten-
ion treatment algorithms suggest other medications as
rst-line and second-line therapy, so clonidine tends to be
rescribed in only the recalcitrant hypertensive patients. In
ddition, clonidine is notorious for severe rebound hyper-
ension when discontinued, so it is typically reserved in our
nstitution for the treatment of unresponsive hypertension.
aken together, these data offer clinicians an opportunity
o make informed decisions regarding patient selection for
AS, which is an important step toward improving out-
omes.
We hypothesized that kidney volume is an important
ariable because it may indirectly reflect the condition of
he end organ for RAS. In the current study, we identified
n association between larger kidney volumes and a favor-
ble BP response to RAS. These data suggest that larger
idney volume is a surrogate marker for kidneys with less
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diatheses more likely to be reversible. The clinical utility of
renal volume calculations may lie in decision making
among patients who would be marginal candidates for
stenting based on the number of antihypertensive medica-
tions. For example, a patient with three-drug hypertension
and a small kidney is unlikely to see any improvement in BP,
whereas the patient with three-drug hypertension and kid-
ney volume 150 cm3 had a 63% probability of improved
BP with RAS.
Another potential use of this predictor relates to pa-
tients with renal insufficiency. Beck et al8 recently reported
that patients with renal insufficiency, defined in their study
as having an estimated glomerular filtration rate 40 mL/
min/1.73m2, were significantly less likely to have a durable
BP response to RAS. In the current study, we carefully
examined the outcomes for patients with a serum creatinine
1.5 mg/dL. In comparing responders and nonre-
sponders within the subset of patients with renal insuffi-
ciency, we found that renal volume of BP responders was
significantly higher than that of nonresponders. Thus, we
Fig 2. Kidney volume and blood pressure (BP) respon
showing 95% confidence intervals) varies according to th
Table V. Independent predictors of blood pressure
response
Predictor ORa (95% CI) P
Requirement for 4 medications 29.9 (5.6-159.4) .0001
Diastolic blood pressure 90 mm Hg 31.4 (4.1-241.6) .0011
Clonidine use 7.3 (1.2-43.5) .029
Ipsilateral kidney volume 150 cm3 3.1 (0.67-14.1) .15
aOdds of blood pressure response to renal artery stenting.believe that patients with renal insufficiency can be treated oith a high likelihood of BP response as long as the
psilateral renal volume is relatively preserved.
Renal volume has recently gained some interest as a
redictor of response outcome for RAS. In a small study of
3 patients, Binkert et al14 found that a normal renal
olume index (renal volume indexed to body mass index)
rovided high sensitivity (91%) but low specificity (33%) in
redicting a favorable outcome for RAS. A more recent
eport from Bommart et al15 examined the relationship
etween renal morphometrics and clinical outcome among
0 patients stented for hypertension and 28 patients treated
or presumed ischemic nephropathy. Among patients with
ypertension, smaller kidney size, characterized by shorter
idney length and lower renal volume (when indexed to
ody mass index), was associated with a higher likelihood
f a favorable BP response to RAS. Their finding directly
ontradicts our finding that a larger kidney volume was
ssociated with a higher probability of BP response. We
elieve that our data are more consistent with the known
athophysiology of progressive renal injury due to renal
rtery stenosis. Moreover, our data are supported by the
bservations of Binkert et al14 in a smaller cohort.
Certainly, however, the findings of Bommart et al are
rovocative and indicate that the relationship between re-
al volumes and outcomes for RAS deserves further inves-
igation. It is worth noting that their end points included
ither a BP or renal function response, while we used only
P response to define responders. In addition, Bommart et
l used different criteria to define BP response than we used
n the current study, which could also account for the
iscrepancies between the two studies. In the current study,
e focused on preoperative renal volume as a predictor of
te. The proportion of BP responders (with error bars
ilateral kidney volume (cm3). P  .007 (2 for trend).se rautcome, but postoperative renal volume also has prognos-
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parenchymal volume loss after RAS had worse long-term
survival and higher rates of progression to dialysis.
The data from the current study have direct implica-
tions for the ASTRAL trial and ongoing Cardiovascular
Outcomes in Renal Atherosclerotic Lesions (CORAL)
trial. The enrollment criteria for the ASTRAL did not
specify any threshold blood pressure or medication require-
ments.3 The CORAL trial included patients with two-drug
hypertension and a systolic BP 155 mm Hg.16 Neither
study incorporated a threshold kidney size for enrollment.
Our data indicate that it is possible these trials have enrolled
patients with a low probability of a favorable BP response,
which could dilute any benefit of RAS in the stented
cohort. Indeed, the ASTRAL trial has already endured
considerable criticism for its ill-defined enrollment crite-
ria.4 In effect, these studies were inherently, albeit inadver-
tently, biased against RAS from the outset based on their
enrollment criteria. In view of data from the current study,
future studies should use more rigorous inclusion criteria if
there is to be any hope of proving conclusively that there is
a benefit to RAS over medical therapy.
Although the current study is highly instructive and
may aid in patient selection for RAS, there are obvious
limitations that must be acknowledged. First, the defini-
tions of a “responder” and “nonresponder” are inherently
subjective, although based on prior reporting guidelines.
Whether a patient who improves from five medications to
four medications after RAS derives any true physiologic
Fig 3. Number of predictors and blood pressure (BP) re
BP response. The numbers of predictors were tallied for e
of predictors on the probability of a BP response to ren
intervals). P  .0001 (2 for trend).benefit is open to conjecture, but that is the nature of fttempting to define outcomes for a dynamic variable such
s BP.
Second, the primary outcome of interest in this study
as BP response, so other end points such as renal function
nd major cardiovascular events were not examined. BP
esponse to RAS is, at best, a surrogate for the future risk of
ardiovascular events. It remains possible, although not
ikely, that RAS could decrease major cardiovascular events
ithout affecting BP.
Third, duplex-derived resistive indexes were not ob-
ained for most patients, so correlations of resistive indexes
ith renal volume measurements was not possible in this
tudy. Furthermore, renal volume calculations in the cur-
ent study consisted of estimates of renal volume calculated
rom three kidney measurements: kidney length, width,
nd depth. This approach did not account for the possibil-
ty of central volume loss associated with enlarged renal
alyces. Increased accuracy may be attained in future stud-
es by using volume-calculating software that are incorpo-
ated intomanymodernCT scanners and image-processing
oftware programs. Such software was not used in the
urrent study because many imaging studies were older,
rchived studies that were often impossible to import into
ur software program.
Finally, the predictors identified in the current study
ill require validation in a different patient population. In
ddition, future studies should attempt to utilize renal
uplex because of the inherent advantages of this modality
se rate. Multivariate analysis identified four predictors of
tient. There is a cumulative effect of increasing numbers
tery stenting (with error bars showing 95% confidencespon
ach pa
al aror screening.
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The current study demonstrated that three preopera-
tive clinical variables—number of medications, diastolic BP
90 mmHg, and clonidine use—may be useful predictors
of BP response to RAS. Patients with none of these predic-
tors present before stenting are highly unlikely to respond
to RAS with improved BP, having a response rate of 1.5% in
our experience. With one predictor, the BP response rate
rose to 45%. Patients with two or more predictors have at
least a 76% probability of BP response. Kidney volume may
help in discriminating responders from nonresponders
among those patients with 3-drug hypertension. Being
cognizant of these predictors of BP response may assist
clinicians in patient selection and provide more concrete
data with which to counsel patients on the likely outcomes
for RAS.
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Dr Julie Ann Freischlag (Baltimore, Md). When you looked
back at the 97 patients that you studied and reviewed all the factors
we thought we knew to be true — medications, creatinine, kidney
size — how are you changing how you choose those patients who
should undergo renal artery intervention? How did you put it all
together? Have you changed what you have done now that you
look forward?
Dr Gregory Modrall. I think we have a very heterogeneous
group of surgeons and radiologists. Clearly, the practice patterns
are different between our radiologists and our surgeons. The
radiologists tend to get patients who were referred from the
outside of the facility. They are asked to provide the technical
expertise of performing renal artery stenting and they do precisely
that.
In our vascular surgery practice, we are more commonly asked
our opinion on the probability of benefit for renal artery stenting.
Because these are new data that have not been externally validated,he unpredictability of outcomes for renal artery stenting.My hope
s that with the use of better predictors of outcome, we can obtain
etter clinical outcomes and people will again feel more comfort-
ble referring patients to us for renal artery stenting.
Dr Freischlag. Having a third get better probably was a little
obering, because you were hoping for a higher number.
Dr Modrall. I would challenge anyone to look at their own
esults. Often, the reality is not as optimistic as one would have
redicted. I think this really speaks to the need for reliable markers
f a favorable outcome from stenting.
Dr Anil Hingorani (Brooklyn, NY). Did you actually look at
he kidney itself in terms of perfusion to the kidney and did you
easure resistive indexes or perfusion to the cortex or such num-
ers?
Dr Modrall. We attempted to look at renal perfusion with the
cans, but there is such a variation in imaging technique between
cans that I don’t find that to be a useful endeavor. Most of the
atients who had renal duplexes performed at referring institutions
r not at all, so the resistive indices were often lacking on this study.
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resistive indexes with kidney volumes.
Dr Wilhelm Sandmann (Düsseldorf, Germany). Your mea-
surement probably looks a little bit too simple to be the answer to
the question: Who should undergo revascularization and who
should not? I think it was 8 years ago that Rademacher from the
Medical School of Hannover published a paper in the New Eng-
land Journal of Medicine showing that there is a threshold if you
measure or calculate the resistive index. Somy question is, How do
your data correspond to the resistive index properly measured in all
segments of both kidneys?
Dr Modrall. As you are probably aware, some centers have
found utility in measuring resistive indexes, but resistive indexes
have been lacking in predictive value in other institutions. Unfor-
tunately, in the current series, only a minority of patients had
resistive indexes measured, so I can’t correlate the resistive indexes
to the kidney volume size. Ideally, both should be obtained and
these data should be used in tandem in the decision-making
process.
Dr John Jeb Hallett (Charleston, SC). Greg, this is a won-
derful paper in terms of giving us something to use in practice. I
have two questions: Are you using this volume measurement
regularly now, and is that done by radiology or done by you? And
the second is, are these recommendations applicable to your sur-
gical revascularization for renal artery disease?
Dr Modrall: This is such a new finding, we have incorporated
it into our practice. We began this study with the intent of doing
computed tomography-based automatic measurements of kidney
volume. And it turns out that when you use some of the volume-
painting or volume-measuring programs in the software, it is
neither automatic nor without considerable subjectivity in the
process. For that reason, we opted to use the volume-estimating
technique we described in this paper. One of the coauthors of this
paper is a radiologist, so I am hopeful that we can begin to
incorporate renal volumemeasurement into our reports of patients
in whom renal artery intervention is being contemplated.
We did not look at surgical revascularization in this study.
Initially, it was our intent to include surgical bypasses in this study.
Currently, we are performing many fewer renal artery bypasses
than in years past, and most of those bypasses are for purposes of
aortic debranching. I would be uncomfortable speculating on the
utility of kidney volume based on such a small subset of patients.
Dr John Blebea (Cleveland, Ohio). The volumemeasurement
calculations seem rather simplistic, as the kidney is not a rectangle.
I have two questions: First, what is the reproducibility of these
volume measurements? The results could easily change depending
on the caliper location, especially of the depth measurements.
Second, were your volume categories and measurement cutoffs
established at the beginning of the study, or did you calculate them
and arbitrarily decide on the particular cutoff values of 150 and 75
after the data were obtained?
Dr Modrall. You are correct. There is subjectivity, although
minimal. Multiple recordings were obtained for each measure-
ment, and there was 5% variation. That is an amount of inter-
measurement variability that I believe makes this technique reason-
ably reproducible.
In terms of the cutoffs, those were based on an assessment of
the graph representing increments of kidney volumes and the
respective blood pressure response rate. Based on those data, the
150 cm3 threshold appeared to be the most appropriate cutoff.
t
dI will note that while we have suggested three clinical predic-
ors and a kidney volume of 150 cm3, it is our intent to validate
hese recommendations in an entirely separate population. I think
e will be more confident in our recommendations with further
alidation.
Dr Vikram Paruchuri (Boston, Mass). Question 1: I would
ssume that considering the age of the cohort, many patients in the
tudy had coronary artery disease, hypertension, or benign prostate
yperplasia. Were diuretics, nitrates, -blockers included in the
ubgroup of patients when you took in the total number of
ntihypertensive medications pre- and postintervention? My sec-
nd question is, large kidneys and increased kidney volume have
een seen in patients with diabetes mellitus and interstitial kidney
isease. Do you know what proportion of your patients had
nterstitial kidney disease and diabetes mellitus?
Dr Modrall. I believe that the proportion with diabetes was
bout 35%. In each case, we attempted to exclude those patients
ith another obvious source for the hypertension or renal insuffi-
iency, such as nephritis. There was one case of nephritis that was
xcluded from the study.
In terms of what medications were included, we struggled
ith this problem. Ultimately, we elected to include all medica-
ions which may impact blood pressure, including diuretics and
itrates. While they may not be primarily prescribed for the pur-
ose of blood pressure control, they clearly have an impact on
lood pressure.
Dr Gregory Moneta (Portland, Ore). As pointed out, the
ngioplasty and Stenting for Renal Artery Lesions (ASTRAL)
rial was largely negative and previous individual case series
xamining renal artery stenting have been largely positive. Your
ase series is, however, also largely negative to my interpreta-
ion. It’s very popular to trash the ASTRAL trial. But, your
eries also indicates the futility of renal artery stenting in many
atients. So, what should we do now? Based on your results and
nterpretation of ASTRAL, has the number of renal artery stents
ecreased in your institution?
Dr Modrall. How do we reconcile the ASTRAL trial with
hese single-center trials? Our data on the blood pressure response
ates based on the number of antihypertensive medications alone
uggest that the entry criteria for the ASTRAL trial and for the
ardiovascular Outcomes in Renal Atherosclerotic Lesions
CORAL) trial were overly liberal. For instance, the CORAL trial
as permitted inclusion of patients with two-drug hypertension. In
ur series, two-drug hypertension equates to a 7% likelihood of a
lood pressure response to renal stenting. By including patients
ith two-drug hypertension in those trials, you’re diluting the
otential benefit. The ASTRAL trial was even more less restrictive
n their enrollment criteria, so there is high likelihood that patients
ith one- and two-drug hypertension were enrolled.
Although these are important trials, they may have been
onceived prematurely. The investigators for these trials did not
ave the data to inform decisions on which patients should be
ncluded and which should not be included in the trial. As a result,
fully expect these trials to provide negative results, just as we saw
n the ASTRAL trial. I now believe we have an explanation for
hose negative results, which is perhaps why it may be appropriate
o repeat those trials with entry criteria that are informed by current
ata.
